Swedish biopharmaceutical company Mendus AB (STO:IMMU) on Wednesday reported positive topline data from the Phase 1 ALISON trial of vididencel in ovarian cancer patients.
Vididencel stimulated immune responses in 12 out of 17 patients, a potential basis for an anti-tumour response.
The trial also confirmed the drug's strong safety profile with only mild side effects.
Long-term follow-up is ongoing, with the next update expected in Q4 2025.
Vivesto strengthens Cantrixil programme with positive preclinical data
Thor Medical signs supply deal with AdvanCell
Abilita and Orion partner on antibody therapeutics for oncology and pain
Breckenridge Pharmaceutical launches FDA approved methadone injection
Pharus Diagnostics unveils liquid biopsy test for early pancreatic cancer detection
Guardant Health and Boehringer Ingelheim partner on lung cancer diagnostic
Mendus reports positive topline data from ovarian cancer trial
Fosun International receives Outstanding ESG Award
Samsung Biologics invests in Generate:Biomedicines
SK Biopharmaceuticals agrees research collaboration with ProEn Therapeutics